Dabrafenib Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Dabrafenib comprises 161 peer-reviewed publications across 15 journals, 11 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Melanoma, Neoplasms, Histiocytosis, Langerhans-Cell, and Glioma. Most recent publication: Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H., JCO Precis Oncol, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Childhood Langerhans cell histiocytosis hematological involvement: severity associated with BRAFV600E loads.
    Thalhammer J, Jeziorski E, Marec-Bérard P, et al. · Blood · 2025
    PubMed: PMID 39486044 · NCT07022834 · Histiocytosis, Langerhans-Cell
  2. Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H.
    Salama AKS, Wang V, Macrae ER, et al. · JCO Precis Oncol · 2026
    PubMed: PMID 41533998 · NCT04439292 · Multiple Myeloma
  3. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
    Ribas A, Lawrence D, Atkinson V, et al. · Nat Med · 2019
    PubMed: PMID 31171879 · NCT02130466 · Melanoma
  4. Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis.
    Parekh D, Lin H, Batajoo A, et al. · Br J Haematol · 2024
    PubMed: PMID 38501389 · NCT07022834 · Histiocytosis, Langerhans-Cell
  5. Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosis.
    Karri V, Lin H, Velazquez J, et al. · Br J Haematol · 2024
    PubMed: PMID 38501390 · NCT07022834 · Histiocytosis, Langerhans-Cell
  6. Efficacy, safety, and quality of life of dabrafenib plus trametinib treatment in Chinese patients with BRAF V600E mutation-positive metastatic non-small cell lung cancer.
    Fan Y, Zhou J, Zhao Y, et al. · Transl Lung Cancer Res · 2025
    PubMed: PMID 39830765 · NCT04452877 · Carcinoma, Non-Small-Cell Lung
  7. BRAFV600E-induced senescence drives Langerhans cell histiocytosis pathophysiology.
    Bigenwald C, Le Berichel J, Wilk CM, et al. · Nat Med · 2021
    PubMed: PMID 33958797 · NCT07022834 · Histiocytosis, Langerhans-Cell
  8. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.
    Ascierto PA, Ferrucci PF, Fisher R, et al. · Nat Med · 2019
    PubMed: PMID 31171878 · NCT02130466 · Melanoma

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT01584648MelanomaProgression-Free Survival (PFS) as Assessed by the Investigator
From randomization until the earliest date of disease progression (PD) or death due to any cause (up to approximately 6 years)
Dabrafenib + Placebo8.8 Months
Dabrafenib + Trametinib10.2 Months
NCT01597908
COMBI-v
MelanomaOverall Survival (OS)
From the date of randomization until date of death due to any cause (up to approximately 6 years)
Dabrafenib Plus Trametinib26.0 Months
Vemurafenib17.8 Months
NCT01682083
COMBI-AD
MelanomaPercentage of Participants With Relapse-free Survival (RFS) Events
Approximately 4 years
Dabrafenib and Trametinib Combination Therapy3 Participants
Dabrafenib and Trametinib Combination Therapy163 Participants
Dabrafenib and Trametinib Combination Therapy43 Participants
Dabrafenib and Trametinib Combination Therapy229 Participants
Dabrafenib and Trametinib Placebos149 Participants
Dabrafenib and Trametinib Placebos35 Participants
Dabrafenib and Trametinib Placebos247 Participants
Dabrafenib and Trametinib Placebos1 Participants
NCT01682083
COMBI-AD
MelanomaRelapse-free Survival (RFS)
Approximately 4 years
Dabrafenib and Trametinib Combination TherapyNA Months
Dabrafenib and Trametinib Placebos16.6 Months
NCT02224781Melanoma2-year Overall Survival (OS)
assessed every 3 months if patient is < 2 years from study entry and every 6 months if patient is 2-5 years from study entry
Arm A (Immunotherapy)0.683 Proportion of participants
Arm B (BRAF Inhibitor Therapy)0.541 Proportion of participants
NCT02967692
COMBI-i
MelanomaBiomarker Cohort (Part 2): Change From Baseline in CD8+ Cells Upon Treatment With Spartalizumab in Combination With Dabrafenib and Trametinib
Baseline, Cycle 1 Day 15 and Cycle 3 Day 1 (Part 2). Each cycle is 28 days
Part 2- Biomarker Cohort: PDR001 400 mg Q4W + Dabrafenib 150 mg BID + Trametinib 2 mg QD1.2 Percentage Marker Area (±2.43 Standard Deviation)
Part 2- Biomarker Cohort: PDR001 400 mg Q4W + Dabrafenib 150 mg BID + Trametinib 2 mg QD0.4 Percentage Marker Area (±3.22 Standard Deviation)
NCT02967692
COMBI-i
MelanomaBiomarker Cohort (Part 2): Change From Baseline in Programmed Cell Death-ligand 1 (PD-L1) Expression Upon Treatment With Spartalizumab in Combination With Dabrafenib and Trametinib
Baseline, Cycle 1 Day 15 and Cycle 3 Day 1 (Part 2). Each cycle is 28 days
Part 2- Biomarker Cohort: PDR001 400 mg Q4W + Dabrafenib 150 mg BID + Trametinib 2 mg QD2.7 Percentage of positive tumor cells (±7.63 Standard Deviation)
Part 2- Biomarker Cohort: PDR001 400 mg Q4W + Dabrafenib 150 mg BID + Trametinib 2 mg QD1.7 Percentage of positive tumor cells (±13.05 Standard Deviation)
NCT02967692
COMBI-i
MelanomaRandomized (Part 3): Progression-Free Survival (PFS) as Per Investigator's Assessment by RECIST 1.1
Up to disease progression or death due to any cause, whichever occurs first, assessed up to 2.8 years (Part 3)
Part 3- Arm 1: PDR001 400 mg Q4W + Dabrafenib 150 mg BID + Trametinib 2 mg QD16.2 Months
Part 3- Arm 2: Placebo + Dabrafenib 150 mg BID + Trametinib 2 mg QD12.0 Months
NCT02967692
COMBI-i
MelanomaSafety Run-In (Part 1): Number of Participants With Dose Limiting Toxicities (DLTs)
Up to 8 weeks (Part 1)
Part 1- Safety run-in: PDR001 400 mg Q4W + Dabrafenib 150 mg BID + Trametinib 2 mg QD1 Participants
NCT03551626
COMBI-APlus
MelanomaComposite Rate of Pyrexia Related Events
Baseline up to 12 months
Dabrafenib+Trametinib7.6 Percentage of participants
NCT04940052—Progression Free Survival (PFS)
From randomization to first documented progression or deaths, whichever comes first, assessed up to approximately 3 years
Dabrafenib Placebo Plus Trametinib Placebo3.7 Months
Dabrafenib Plus Trametinib12.8 Months

Publications by year

2004–2026: 161 publications.

2004
1
2008
1
2009
1
2011
1
2012
3
2013
3
2014
3
2015
6
2016
7
2017
10
2018
3
2019
11
2020
16
2021
11
2022
18
2023
28
2024
19
2025
11
2026
8

Publications by indication

Melanoma (73)

  • Phase II Study of Vismodegib in Patients With SMO- or PTCH1-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T.
    JCO Precis Oncol · 2025 · PMID 41066729 · NCT02465060
  • Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial.
    Lancet Oncol · 2025 · PMID 40250457 · NCT01682083
  • PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.
    JCO Precis Oncol · 2025 · PMID 40865033 · NCT02465060
  • Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H.
    JCO Precis Oncol · 2025 · PMID 39913886 · NCT02465060
  • Mitochondrial bioenergetics and networks in melanoma: an update.
    Apoptosis · 2025 · PMID 40721981 · NCT01989585

Neoplasms (43)

  • Prospective evaluation of genomics-guided off-label treatment.
    Nature · 2026 · PMID 41986720 · NCT02925234
  • Temsirolimus in Patients With Solid Tumors With PIK3CA Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
    JCO Precis Oncol · 2026 · PMID 42018965 · NCT02693535
  • Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway).
    Front Oncol · 2026 · PMID 36910668 · NCT03239015
  • Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.
    JCO Precis Oncol · 2026 · PMID 42060861 · NCT02693535
  • Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
    JCO Precis Oncol · 2026 · PMID 41538762 · NCT02693535

Histiocytosis, Langerhans-Cell (17)

  • Childhood Langerhans cell histiocytosis hematological involvement: severity associated with BRAFV600E loads.
    Blood · 2025 · PMID 39486044 · NCT07022834
  • Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis.
    Br J Haematol · 2024 · PMID 38501389 · NCT07022834
  • Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosis.
    Br J Haematol · 2024 · PMID 38501390 · NCT07022834
  • Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders.
    Haematologica · 2024 · PMID 37731389 · NCT07022834
  • Dabrafenib, alone or in combination with trametinib, in BRAF V600-mutated pediatric Langerhans cell histiocytosis.
    Blood Adv · 2023 · PMID 36884302 · NCT07022834

Glioma (5)

  • Cost-Effectiveness of Dabrafenib Plus Trametinib Versus Standard Chemotherapy in BRAFV600E-Mutant Pediatric Low-Grade Glioma.
    JCO Oncol Pract · 2026 · PMID 41740060 · NCT02684058
  • FDA Approval Summary: Dabrafenib in Combination with Trametinib for BRAFV600E Mutation-Positive Low-Grade Glioma.
    Clin Cancer Res · 2024 · PMID 37610803 · NCT02684058
  • Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory BRAF V600-Mutant Pediatric High-Grade Glioma.
    J Clin Oncol · 2023 · PMID 37643378 · NCT02684058
  • Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations.
    N Engl J Med · 2023 · PMID 37733309 · NCT02684058
  • Association of BRAF V600E mutations with vasoactive intestinal peptide syndrome in MYCN-amplified neuroblastoma.
    Pediatr Blood Cancer · 2022 · PMID 34331515 · NCT02684058

Neoplasm Metastasis (4)

  • Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications.
    Semin Cancer Biol · 2025 · PMID 39863139 · NCT03878524
  • Molecular profiling of advanced soft-tissue sarcomas: the MULTISARC randomized trial.
    BMC Cancer · 2022 · PMID 34740331 · NCT03784014
  • Feasibility of high-throughput sequencing in clinical routine cancer care: lessons from the cancer pilot project of the France Genomic Medicine 2025 plan.
    ESMO Open · 2021 · PMID 32713836 · NCT03784014
  • Is There Value in Molecular Profiling of Soft-Tissue Sarcoma?
    Curr Treat Options Oncol · 2019 · PMID 30523434 · NCT03784014

Histiocytosis (3)

  • Ophthalmologic Findings in Pediatric Erdheim-Chester Disease: A Literature Review With a Novel Case Report.
    Ophthalmic Plast Reconstr Surg · 2024 · PMID 36877575 · NCT02281760
  • Erdheim-Chester disease.
    Curr Rheumatol Rep · 2014 · PMID 24532298 · NCT02281760
  • Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation.
    Blood · 2013 · PMID 23258922 · NCT02281760

Publications by journal

Trial-results highlights

In the NCT01584648 trial for melanoma, the median progression-free survival was 8.8 months for the Dabrafenib + Placebo arm and **10.2 months** for the Dabrafenib + Trametinib arm. The NCT01597908 (COMBI-v) trial reported a median overall survival of **26.0 months** for the Dabrafenib Plus Trametinib arm, compared to 17.8 months for the Vemurafenib arm. In another melanoma study, NCT02224781, the 2-year overall survival was a proportion of 0.683 for Arm A (Immunotherapy) and **0.541** for Arm B (BRAF Inhibitor Therapy). For the randomized Part 3 of NCT02967692 (COMBI-i), the median progression-free survival was **16.2 months** for the PDR001 400 mg Q4W + Dabrafenib 150 mg BID + Trametinib 2 mg QD arm and 12.0 months for the Placebo + Dabrafenib 150 mg BID + Trametinib 2 mg QD arm.

In the NCT01682083 (COMBI-AD) trial, the number of participants with relapse-free survival events in the Dabrafenib and Trametinib Combination Therapy arm included 3 participants, **163 participants**, 43 participants, and 229 participants. For the Dabrafenib and Trametinib Placebos arm, there were 149 participants and 35 participants with relapse-free survival events. Regarding relapse-free survival in NCT01682083, the median for the Dabrafenib and Trametinib Placebos arm was **16.6 months**, while the median for the Dabrafenib and Trametinib Combination Therapy arm was not available. The NCT02967692 (COMBI-i) trial also explored biomarker changes in its Part 2. Mean changes from baseline in CD8+ cells for the PDR001 400 mg Q4W + Dabrafenib 150 mg BID + Trametinib 2 mg QD arm were **1.2 percentage marker area** and 0.4 percentage marker area. For changes from baseline in Programmed Cell Death-ligand 1 (PD-L1) expression in the same arm, mean values were **2.7 percentage of positive tumor cells** and 1.7 percentage of positive tumor cells.

All values are sourced from primary registry reporting, and individual papers should be consulted for clinical decisions.

All Dabrafenib publications (161)

2026 (8 papers)

  1. Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H.
    Salama AKS, Wang V, Macrae ER, et al. · JCO Precis Oncol · 2026 · Trial result
    PubMed: PMID 41533998 · NCT04439292 · Multiple Myeloma
  2. Prospective evaluation of genomics-guided off-label treatment.
    Verkerk K, Spiekman AC, Haj Mohammad SF, et al. · Nature · 2026 · Derived
    PubMed: PMID 41986720 · NCT02925234 (DRUP) · Neoplasms
  3. Temsirolimus in Patients With Solid Tumors With PIK3CA Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
    Pisick E, Rothe M, Garrett-Mayer E, et al. · JCO Precis Oncol · 2026 · Derived
    PubMed: PMID 42018965 · NCT02693535 (TAPUR) · Neoplasms
  4. Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway).
    Jiao XD, Qin BD, Wang Z, et al. · Front Oncol · 2026 · Derived
    PubMed: PMID 36910668 · NCT03239015 · Neoplasms
  5. Cost-Effectiveness of Dabrafenib Plus Trametinib Versus Standard Chemotherapy in BRAFV600E-Mutant Pediatric Low-Grade Glioma.
    Gascon B, Gauvreau C, Yang A, et al. · JCO Oncol Pract · 2026 · Derived
    PubMed: PMID 41740060 · NCT02684058 · Glioma
  6. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.
    Cobain EF, Rothe M, Garrett-Mayer E, et al. · JCO Precis Oncol · 2026 · Derived
    PubMed: PMID 42060861 · NCT02693535 (TAPUR) · Neoplasms
  7. Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
    Carrizosa DR, Rothe M, Mangat PK, et al. · JCO Precis Oncol · 2026 · Derived
    PubMed: PMID 41538762 · NCT02693535 (TAPUR) · Neoplasms
  8. Lesional dosimetry in 131I refractory metastatic differentiated thyroid cancer with BRAFp.V600E or RAS mutation treated with trametinib +/- dabrafenib followed by radioactive iodine.
    Anizan N, Pignard A, Borget I, et al. · Phys Med · 2026 · Derived
    PubMed: PMID 41861727 · NCT03244956 (MERAIODE)

2025 (11 papers)

  1. Childhood Langerhans cell histiocytosis hematological involvement: severity associated with BRAFV600E loads.
    Thalhammer J, Jeziorski E, Marec-Bérard P, et al. · Blood · 2025 · Trial result
    PubMed: PMID 39486044 · NCT07022834 · Histiocytosis, Langerhans-Cell
  2. Efficacy, safety, and quality of life of dabrafenib plus trametinib treatment in Chinese patients with BRAF V600E mutation-positive metastatic non-small cell lung cancer.
    Fan Y, Zhou J, Zhao Y, et al. · Transl Lung Cancer Res · 2025 · Trial result
    PubMed: PMID 39830765 · NCT04452877 · Carcinoma, Non-Small-Cell Lung
  3. Phase II Study of Vismodegib in Patients With SMO- or PTCH1-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T.
    Tsao AS, Song Z, Ho AL, et al. · JCO Precis Oncol · 2025 · Derived
    PubMed: PMID 41066729 · NCT02465060 · Melanoma
  4. Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications.
    Tost J, Ak-Aksoy S, Campa D, et al. · Semin Cancer Biol · 2025 · Derived
    PubMed: PMID 39863139 · NCT03878524 · Neoplasm Metastasis
  5. Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial.
    Syeda MM, Long GV, Garrett J, et al. · Lancet Oncol · 2025 · Derived
    PubMed: PMID 40250457 · NCT01682083 (COMBI-AD) · Melanoma
  6. Prevalence of targetable genomic alterations among a diverse population participating in the ASCO TAPUR Study.
    Mangat PK, Kirkwood MK, Hinshaw DC, et al. · NPJ Precis Oncol · 2025 · Derived
    PubMed: PMID 40610648 · NCT02693535 (TAPUR) · Neoplasms
  7. PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.
    Janku F, Jegede OA, Puhalla SL, et al. · JCO Precis Oncol · 2025 · Derived
    PubMed: PMID 40865033 · NCT02465060 · Melanoma
  8. Precision treatment guided by patient-derived organoids-based drug testing for locally advanced thyroid cancer: a single arm, phase 2 study.
    Guo Z, Liu J, Zhang X, et al. · Endocrine · 2025 · Derived
    PubMed: PMID 40304938 · NCT06482086
  9. Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H.
    Gouda MA, Wei Z, Rodon J, et al. · JCO Precis Oncol · 2025 · Derived
    PubMed: PMID 39913886 · NCT02465060 · Melanoma
  10. Mitochondrial bioenergetics and networks in melanoma: an update.
    Giannitti G, Paganoni AJJ, Marchesi S, et al. · Apoptosis · 2025 · Derived
    PubMed: PMID 40721981 · NCT01989585 · Melanoma
  11. Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
    Al Baghdadi T, Rothe M, Mangat PK, et al. · JCO Precis Oncol · 2025 · Derived
    PubMed: PMID 41100773 · NCT02693535 (TAPUR) · Neoplasms

2024 (19 papers)

  1. Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis.
    Parekh D, Lin H, Batajoo A, et al. · Br J Haematol · 2024 · Trial result
    PubMed: PMID 38501389 · NCT07022834 · Histiocytosis, Langerhans-Cell
  2. Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosis.
    Karri V, Lin H, Velazquez J, et al. · Br J Haematol · 2024 · Trial result
    PubMed: PMID 38501390 · NCT07022834 · Histiocytosis, Langerhans-Cell
  3. Neoadjuvant BRAF-targeted therapy for ameloblastoma of the mandible: an organ preservation approach.
    Grynberg S, Vered M, Shapira-Frommer R, et al. · J Natl Cancer Inst · 2024 · Trial result
    PubMed: PMID 37966914 · NCT06819605 (NETCAM-RCT) · Ameloblastoma
  4. The Effect of Conservative vs. Radical Treatment of Ameloblastoma on Recurrence Rate and Quality of Life: An Umbrella Review.
    Gasparro R, Giordano F, Campana MD, et al. · J Clin Med · 2024 · Trial result
    PubMed: PMID 39274556 · NCT06819605 (NETCAM-RCT) · Ameloblastoma
  5. Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders.
    Cournoyer E, Ferrell J, Sharp S, et al. · Haematologica · 2024 · Trial result
    PubMed: PMID 37731389 · NCT07022834 · Histiocytosis, Langerhans-Cell
  6. Ophthalmologic Findings in Pediatric Erdheim-Chester Disease: A Literature Review With a Novel Case Report.
    Yeager LB, Grimes JM, Dal Col AK, et al. · Ophthalmic Plast Reconstr Surg · 2024 · Derived
    PubMed: PMID 36877575 · NCT02281760 · Histiocytosis
  7. Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
    Worden FP, Pisick E, Rothe M, et al. · JCO Precis Oncol · 2024 · Derived
    PubMed: PMID 39413339 · NCT02693535 (TAPUR) · Neoplasms
  8. Revolutionizing cancer drug development: Harnessing the potential of basket trials.
    Subbiah V, Burris HA, Kurzrock R, et al. · Cancer · 2024 · Derived
    PubMed: PMID 37934000 · NCT02465060 · Melanoma
  9. Talazoparib in Patients With Solid Tumors With BRCA1/2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study.
    Srkalovic G, Rothe M, Mangat PK, et al. · JCO Precis Oncol · 2024 · Derived
    PubMed: PMID 38865672 · NCT02693535 (TAPUR) · Neoplasms
  10. Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study.
    Schuetze S, Rothe M, Mangat PK, et al. · JCO Precis Oncol · 2024 · Derived
    PubMed: PMID 39013131 · NCT02693535 (TAPUR) · Neoplasms
  11. Concordance in Molecular Tumor Board Case Reviews in the ASCO TAPUR Study.
    Perez JK, Kleber J, Rothe M, et al. · JCO Precis Oncol · 2024 · Derived
    PubMed: PMID 38564684 · NCT02693535 (TAPUR) · Neoplasms
  12. Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.
    Long GV, Hauschild A, Santinami M, et al. · N Engl J Med · 2024 · Derived
    PubMed: PMID 38899716 · NCT01682083 (COMBI-AD) · Melanoma
  13. Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial.
    Long GV, Carlino MS, Au-Yeung G, et al. · Nat Med · 2024 · Derived
    PubMed: PMID 38907159 · NCT02858921 (Neo Trio) · Melanoma
  14. Phase II Study of Sunitinib in Tumors With c-KIT Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V.
    Gien LT, Song Z, Poklepovic A, et al. · JCO Precis Oncol · 2024 · Derived
    PubMed: PMID 39666929 · NCT02465060 · Melanoma
  15. Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol.
    Geurts BS, Zeverijn LJ, Leek LVM, et al. · Clin Cancer Res · 2024 · Derived
    PubMed: PMID 38630551 · NCT02925234 (DRUP) · Neoplasms
  16. Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
    Cannon TL, Rothe M, Mangat PK, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 38748939 · NCT02693535 (TAPUR) · Neoplasms
  17. Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.
    Calfa CJ, Rothe M, Mangat PK, et al. · JCO Precis Oncol · 2024 · Derived
    PubMed: PMID 38354330 · NCT02693535 (TAPUR) · Neoplasms
  18. FDA Approval Summary: Dabrafenib in Combination with Trametinib for BRAFV600E Mutation-Positive Low-Grade Glioma.
    Barbato MI, Nashed J, Bradford D, et al. · Clin Cancer Res · 2024 · Derived
    PubMed: PMID 37610803 · NCT02684058 · Glioma
  19. A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers.
    Algazi AP, Moon J, Lao CD, et al. · Cancer · 2024 · Derived
    PubMed: PMID 38261444 · NCT01902173 · Melanoma

2023 (28 papers)

  1. Dabrafenib, alone or in combination with trametinib, in BRAF V600-mutated pediatric Langerhans cell histiocytosis.
    Whitlock JA, Geoerger B, Dunkel IJ, et al. · Blood Adv · 2023 · Trial result
    PubMed: PMID 36884302 · NCT07022834 · Histiocytosis, Langerhans-Cell
  2. Marked Improvement in Soft Tissue and CNS Manifestations of Adult Langerhans Cell Histiocytosis on Targeted MEK Inhibitor Therapy.
    Lin HT, Wikenheiser-Brokamp KA, Udstuen G, et al. · Chest · 2023 · Trial result
    PubMed: PMID 36759117 · NCT07022834 · Histiocytosis, Langerhans-Cell
  3. Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E-positive LCH.
    Evseev D, Osipova D, Kalinina I, et al. · Blood Adv · 2023 · Trial result
    PubMed: PMID 37216396 · NCT07022834 · Histiocytosis, Langerhans-Cell
  4. Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.
    Zeverijn LJ, Looze EJ, Thavaneswaran S, et al. · Int J Cancer · 2023 · Derived
    PubMed: PMID 37424386 · NCT02925234 (DRUP) · Neoplasms
  5. Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study.
    Yang ES, Halabi S, Rothe M, et al. · JCO Precis Oncol · 2023 · Derived
    PubMed: PMID 36753688 · NCT02693535 (TAPUR) · Neoplasms
  6. Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2.
    Wisinski KB, Flamand Y, Wilson MA, et al. · JCO Precis Oncol · 2023 · Derived
    PubMed: PMID 37053535 · NCT02465060 · Melanoma
  7. Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial.
    Tian J, Chen JH, Chao SX, et al. · Nat Med · 2023 · Derived
    PubMed: PMID 36702949 · NCT03668431 · Colorectal Neoplasms
  8. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial.
    Subbiah V, Kreitman RJ, Wainberg ZA, et al. · Nat Med · 2023 · Derived
    PubMed: PMID 37059834 · NCT02034110 · Neoplasms
  9. IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation.
    Rozeman EA, Versluis JM, Sikorska K, et al. · J Immunother Cancer · 2023 · Derived
    PubMed: PMID 37479483 · NCT02625337 (IMPemBra) · Melanoma
  10. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
    Rohatgi N, Rothe M, Mangat PK, et al. · JCO Precis Oncol · 2023 · Derived
    PubMed: PMID 38039429 · NCT02693535 (TAPUR) · Neoplasms
  11. Pan-cancer efficacy and safety of anlotinib plus PD-1 inhibitor in refractory solid tumor: A single-arm, open-label, phase II trial.
    Qin BD, Jiao XD, Wang Z, et al. · Int J Cancer · 2023 · Derived
    PubMed: PMID 37155342 · NCT03239015 · Neoplasms
  12. The NCI-MATCH trial: lessons for precision oncology.
    O'Dwyer PJ, Gray RJ, Flaherty KT, et al. · Nat Med · 2023 · Derived
    PubMed: PMID 37322121 · NCT02465060 · Melanoma
  13. Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF-mutant solid tumors.
    Mooradian MJ, Cleary JM, Giobbie-Hurder A, et al. · Cancer · 2023 · Derived
    PubMed: PMID 37042037 · NCT02097225 · Melanoma
  14. Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.
    Meric-Bernstam F, Rothe M, Mangat PK, et al. · JCO Precis Oncol · 2023 · Derived
    PubMed: PMID 38096472 · NCT02693535 (TAPUR) · Neoplasms
  15. The Targeted Agent and Profiling Utilization Registry Study: A pragmatic clinical trial.
    Mangat PK, Garrett-Mayer E, Perez JK, et al. · Clin Trials · 2023 · Derived
    PubMed: PMID 37489819 · NCT02693535 (TAPUR) · Neoplasms
  16. Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanoma.
    Li SN, Wan X, Peng LB, et al. · BMC Health Serv Res · 2023 · Derived
    PubMed: PMID 36653848 · NCT01682083 (COMBI-AD) · Melanoma
  17. MERAIODE: A Phase II Redifferentiation Trial with Trametinib and 131I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated Thyroid Cancer.
    Leboulleux S, Benisvy D, Taieb D, et al. · Thyroid · 2023 · Derived
    PubMed: PMID 37350119 · NCT03244956 (MERAIODE)
  18. Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia.
    Kreitman RJ, Moreau P, Ravandi F, et al. · Blood · 2023 · Derived
    PubMed: PMID 36108341 · NCT02034110 · Neoplasms
  19. Fibronectin Contributes to a BRAF Inhibitor-driven Invasive Phenotype in Thyroid Cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2.
    Hicks HM, Pozdeyev N, Sams SB, et al. · Mol Cancer Res · 2023 · Derived
    PubMed: PMID 37219859 · NCT02034110 · Neoplasms
  20. Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory BRAF V600-Mutant Pediatric High-Grade Glioma.
    Hargrave DR, Terashima K, Hara J, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 37643378 · NCT02684058 · Glioma
  21. Neoadjuvant treatment for stage III and IV cutaneous melanoma.
    Gorry C, McCullagh L, O'Donnell H, et al. · Cochrane Database Syst Rev · 2023 · Derived
    PubMed: PMID 36648215 · NCT02858921 (Neo Trio) · Melanoma
  22. Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.
    Geurts BS, Battaglia TW, van Berge Henegouwen JM, et al. · BMC Cancer · 2023 · Derived
    PubMed: PMID 36870947 · NCT02925234 (DRUP) · Neoplasms
  23. Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study.
    Ganti AK, Rothe M, Mangat PK, et al. · JCO Precis Oncol · 2023 · Derived
    PubMed: PMID 37315265 · NCT02693535 (TAPUR) · Neoplasms
  24. Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.
    Duvivier HL, Rothe M, Mangat PK, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 37561967 · NCT02693535 (TAPUR) · Neoplasms
  25. Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations.
    Bouffet E, Hansford JR, Garrè ML, et al. · N Engl J Med · 2023 · Derived
    PubMed: PMID 37733309 · NCT02684058 · Glioma
  26. Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600-Mutant Low-Grade Glioma.
    Bouffet E, Geoerger B, Moertel C, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 36375115 · NCT02124772 · Neoplasms
  27. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.
    Atkins MB, Lee SJ, Chmielowski B, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 36166727 · NCT02224781 · Melanoma
  28. Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study.
    Ahn ER, Rothe M, Mangat PK, et al. · JCO Precis Oncol · 2023 · Derived
    PubMed: PMID 37027810 · NCT02693535 (TAPUR) · Neoplasms

2022 (18 papers)

  1. Molecular profiling of advanced soft-tissue sarcomas: the MULTISARC randomized trial.
    Italiano A, Dinart D, Soubeyran I, et al. · BMC Cancer · 2022 · Trial result
    PubMed: PMID 34740331 · NCT03784014 (MULTISARC) · Neoplasm Metastasis
  2. Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial.
    Busaidy NL, Konda B, Wei L, et al. · Thyroid · 2022 · Trial result
    PubMed: PMID 35658604 · NCT01723202 · Thyroid Neoplasms
  3. Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial.
    Wen PY, Stein A, van den Bent M, et al. · Lancet Oncol · 2022 · Derived
    PubMed: PMID 34838156 · NCT02034110 · Neoplasms
  4. Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy.
    Wang Y, Liu S, Yang Z, et al. · Cancer Cell · 2022 · Derived
    PubMed: PMID 34416167 · NCT02196181 · Melanoma
  5. Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature.
    van Berge Henegouwen JM, van der Wijngaart H, Zeverijn LJ, et al. · Cancer Chemother Pharmacol · 2022 · Derived
    PubMed: PMID 35598186 · NCT02925234 (DRUP) · Neoplasms
  6. Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i).
    Tawbi HA, Robert C, Brase JC, et al. · J Immunother Cancer · 2022 · Derived
    PubMed: PMID 35728875 · NCT02967692 (COMBI-i) · Melanoma
  7. Association of BRAF V600E mutations with vasoactive intestinal peptide syndrome in MYCN-amplified neuroblastoma.
    Shahid S, Kushner BH, Modak S, et al. · Pediatr Blood Cancer · 2022 · Derived
    PubMed: PMID 34331515 · NCT02684058 · Glioma
  8. Platelet p110β mediates platelet-leukocyte interaction and curtails bacterial dissemination in pneumococcal pneumonia.
    Schrottmaier WC, Kral-Pointner JB, Salzmann M, et al. · Cell Rep · 2022 · Derived
    PubMed: PMID 36351402 · NCT02465060 · Melanoma
  9. Evaluation of the Effects of Repeat-Dose Dabrafenib on the Single-Dose Pharmacokinetics of Rosuvastatin (OATP1B1/1B3 Substrate) and Midazolam (CYP3A4 Substrate).
    Nebot N, Won CS, Moreno V, et al. · Clin Pharmacol Drug Dev · 2022 · Derived
    PubMed: PMID 33932130 · NCT02082665 · Melanoma
  10. Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma.
    Nakauma-González JA, Rijnders M, van Riet J, et al. · Eur Urol · 2022 · Derived
    PubMed: PMID 35086719 · NCT02925234 (DRUP) · Neoplasms
  11. Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial.
    Mao L, Ding Y, Bai X, et al. · Front Oncol · 2022 · Derived
    PubMed: PMID 34504796 · NCT02083354 · Melanoma
  12. KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation.
    Maio M, Carlino MS, Joshua AM, et al. · Eur J Cancer · 2022 · Derived
    PubMed: PMID 34801354 · NCT02130466 · Melanoma
  13. Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I.
    Krop IE, Jegede OA, Grilley-Olson JE, et al. · JCO Precis Oncol · 2022 · Derived
    PubMed: PMID 35138919 · NCT02465060 · Melanoma
  14. Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study.
    Gupta R, Meric-Bernstam F, Rothe M, et al. · JCO Precis Oncol · 2022 · Derived
    PubMed: PMID 36315917 · NCT02693535 (TAPUR) · Neoplasms
  15. Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma.
    Dummer R, Long GV, Robert C, et al. · J Clin Oncol · 2022 · Derived
    PubMed: PMID 35030011 · NCT02967692 (COMBI-i) · Melanoma
  16. Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F.
    Damodaran S, Zhao F, Deming DA, et al. · J Clin Oncol · 2022 · Derived
    PubMed: PMID 35133871 · NCT02465060 · Melanoma
  17. Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus.
    Atkinson V, Robert C, Grob JJ, et al. · Eur J Cancer · 2022 · Derived
    PubMed: PMID 35042070 · NCT03551626 (COMBI-APlus) · Melanoma
  18. Clinical trial results show promise of targeting autophagy BRAF mutant melanoma.
    Amaravadi RK · Autophagy · 2022 · Derived
    PubMed: PMID 35156519 · NCT02257424 (BAMM)

2021 (11 papers)

  1. Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H.
    Salama AKS, Li S, Macrae ER, et al. · J Clin Oncol · 2021 · Trial result
    PubMed: PMID 32758030 · NCT04439292 · Multiple Myeloma
  2. Feasibility of high-throughput sequencing in clinical routine cancer care: lessons from the cancer pilot project of the France Genomic Medicine 2025 plan.
    FGM 2025 Workflow Study Group (Alliance nationale des Sciences de la Vie et de la Santé), Auzanneau C, Bacq D, et al. · ESMO Open · 2021 · Trial result
    PubMed: PMID 32713836 · NCT03784014 (MULTISARC) · Neoplasm Metastasis
  3. BRAFV600E-induced senescence drives Langerhans cell histiocytosis pathophysiology.
    Bigenwald C, Le Berichel J, Wilk CM, et al. · Nat Med · 2021 · Trial result
    PubMed: PMID 33958797 · NCT07022834 · Histiocytosis, Langerhans-Cell
  4. Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study.
    Syeda MM, Wiggins JM, Corless BC, et al. · Lancet Oncol · 2021 · Derived
    PubMed: PMID 33587894 · NCT02039947 · Melanoma
  5. Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers.
    Schadendorf D, Robert C, Dummer R, et al. · Eur J Cancer · 2021 · Derived
    PubMed: PMID 34225229 · NCT01336634 · Neoplasms
  6. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH).
    Flaherty KT, Gray RJ, Chen AP, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 33048619 · NCT02465060 · Melanoma
  7. Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
    Fisher JG, Tait D, Garrett-Mayer E, et al. · Target Oncol · 2021 · Derived
    PubMed: PMID 33090333 · NCT02693535 (TAPUR) · Neoplasms
  8. Catastrophic ATP loss underlies a metabolic combination therapy tailored for MYCN-amplified neuroblastoma.
    Dalton KM, Lochmann TL, Floros KV, et al. · Proc Natl Acad Sci U S A · 2021 · Derived
    PubMed: PMID 33762304 · NCT03026517 · Melanoma
  9. Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W.
    Chae YK, Hong F, Vaklavas C, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 32463741 · NCT02465060 · Melanoma
  10. Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
    Alva AS, Mangat PK, Garrett-Mayer E, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 33844595 · NCT02693535 (TAPUR) · Neoplasms
  11. Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
    Al Baghdadi T, Garrett-Mayer E, Halabi S, et al. · Target Oncol · 2021 · Derived
    PubMed: PMID 33068284 · NCT02693535 (TAPUR) · Neoplasms

2020 (16 papers)

  1. Langerhans cell histiocytosis.
    Rodriguez-Galindo C, Allen CE · Blood · 2020 · Trial result
    PubMed: PMID 32106306 · NCT07022834 · Histiocytosis, Langerhans-Cell
  2. Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study.
    Donadieu J, Larabi IA, Tardieu M, et al. · J Clin Oncol · 2020 · Trial result
    PubMed: PMID 31513482 · NCT07022834 · Histiocytosis, Langerhans-Cell
  3. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.
    Subbiah V, Lassen U, Élez E, et al. · Lancet Oncol · 2020 · Derived
    PubMed: PMID 32818466 · NCT02034110 · Neoplasms
  4. Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma.
    Si L, Zhang X, Shin SJ, et al. · Eur J Cancer · 2020 · Derived
    PubMed: PMID 32534242 · NCT02083354 · Melanoma
  5. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial.
    Schadendorf D, Hauschild A, Santinami M, et al. · Lancet Oncol · 2020 · Derived
    PubMed: PMID 30928620 · NCT01682083 (COMBI-AD) · Melanoma
  6. PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma.
    Ribas A, Algazi A, Ascierto PA, et al. · Nat Commun · 2020 · Derived
    PubMed: PMID 33288749 · NCT02027961 · Melanoma
  7. KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer.
    Owen DH, Konda B, Sipos J, et al. · J Natl Compr Canc Netw · 2020 · Derived
    PubMed: PMID 31085763 · NCT01723202 · Thyroid Neoplasms
  8. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial.
    Long GV, Saw RPM, Lo S, et al. · Lancet Oncol · 2020 · Derived
    PubMed: PMID 31171444 · NCT01972347 (Neo Combi) · Melanoma
  9. Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia.
    Kim HY, Duong JK, Gonzalez M, et al. · Cancer Chemother Pharmacol · 2020 · Derived
    PubMed: PMID 30661097 · NCT01972347 (Neo Combi) · Melanoma
  10. A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation-Positive Solid Tumors.
    Kieran MW, Geoerger B, Dunkel IJ, et al. · Clin Cancer Res · 2020 · Derived
    PubMed: PMID 31506385 · NCT01677741 · Brain Neoplasms
  11. Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma.
    Hauschild A, Dummer R, Schadendorf D, et al. · J Clin Oncol · 2020 · Derived
    PubMed: PMID 30343620 · NCT01682083 (COMBI-AD) · Melanoma
  12. Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study.
    Hargrave DR, Bouffet E, Tabori U, et al. · Clin Cancer Res · 2020 · Derived
    PubMed: PMID 31811016 · NCT01677741 · Brain Neoplasms
  13. Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i.
    Dummer R, Lebbé C, Atkinson V, et al. · Nat Med · 2020 · Derived
    PubMed: PMID 33020648 · NCT02967692 (COMBI-i) · Melanoma
  14. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.
    Dummer R, Hauschild A, Santinami M, et al. · N Engl J Med · 2020 · Derived
    PubMed: PMID 32877599 · NCT01682083 (COMBI-AD) · Melanoma
  15. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial.
    Dummer R, Brase JC, Garrett J, et al. · Lancet Oncol · 2020 · Derived
    PubMed: PMID 32007138 · NCT01682083 (COMBI-AD) · Melanoma
  16. Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial.
    Algazi AP, Othus M, Daud AI, et al. · Nat Med · 2020 · Derived
    PubMed: PMID 33020646 · NCT02196181 · Melanoma

2019 (11 papers)

  1. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
    Ribas A, Lawrence D, Atkinson V, et al. · Nat Med · 2019 · Trial result
    PubMed: PMID 31171879 · NCT02130466 · Melanoma
  2. RAF/MEK/extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions.
    Hogstad B, Berres ML, Chakraborty R, et al. · J Exp Med · 2019 · Trial result
    PubMed: PMID 29263218 · NCT07022834 · Histiocytosis, Langerhans-Cell
  3. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.
    Ascierto PA, Ferrucci PF, Fisher R, et al. · Nat Med · 2019 · Trial result
    PubMed: PMID 31171878 · NCT02130466 · Melanoma
  4. A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.
    Wang J, Yao Z, Jonsson P, et al. · Cancer Discov · 2019 · Derived
    PubMed: PMID 29880583 · NCT01677741 · Brain Neoplasms
  5. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
    Subbiah V, Kreitman RJ, Wainberg ZA, et al. · J Clin Oncol · 2019 · Derived
    PubMed: PMID 29072975 · NCT02034110 · Neoplasms
  6. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
    Robert C, Grob JJ, Stroyakovskiy D, et al. · N Engl J Med · 2019 · Derived
    PubMed: PMID 31166680 · NCT01584648 · Melanoma
  7. Is time to progression associated with post-progression survival in previously treated metastatic non-small cell lung cancer with BRAF V600E mutation? A secondary analysis of phase II clinical trial data.
    Li J, Sasane M, Zhang J, et al. · BMJ Open · 2019 · Derived
    PubMed: PMID 30121602 · NCT01336634 · Neoplasms
  8. Targeting BRAF Mutations in High-Grade Neuroendocrine Carcinoma of the Colon.
    Burkart J, Owen D, Shah MH, et al. · J Natl Compr Canc Netw · 2019 · Derived
    PubMed: PMID 30181415 · NCT01713972
  9. New NCCN Guidelines for Uveal Melanoma and Treatment of Recurrent or Progressive Distant Metastatic Melanoma.
    Barker CA, Salama AK · J Natl Compr Canc Netw · 2019 · Derived
    PubMed: PMID 29784747 · NCT02224781 · Melanoma
  10. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
    Amaria RN, Prieto PA, Tetzlaff MT, et al. · Lancet Oncol · 2019 · Derived
    PubMed: PMID 29361468 · NCT02231775 · Melanoma
  11. Is There Value in Molecular Profiling of Soft-Tissue Sarcoma?
    Italiano A · Curr Treat Options Oncol · 2019 · Background
    PubMed: PMID 30523434 · NCT03784014 (MULTISARC) · Neoplasm Metastasis

2018 (3 papers)

  1. BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis.
    Patel KR, Chowdhary M, Switchenko JM, et al. · Melanoma Res · 2018 · Derived
    PubMed: PMID 27223498 · NCT01721603 · Melanoma
  2. An open-label phase I dose-finding study of APR-246 in hematological malignancies.
    Deneberg S, Cherif H, Lazarevic V, et al. · Blood Cancer J · 2018 · Background
    PubMed: PMID 27421096 · NCT03391050 · Melanoma
  3. Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial.
    Andtbacka RH, Ross M, Puzanov I, et al. · Ann Surg Oncol · 2018 · Background
    PubMed: PMID 27342831 · NCT03972046 · Melanoma

2017 (10 papers)

  1. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.
    Schreuer M, Jansen Y, Planken S, et al. · Lancet Oncol · 2017 · Derived
    PubMed: PMID 28268064 · NCT02296996 · Melanoma
  2. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.
    Planchard D, Smit EF, Groen HJM, et al. · Lancet Oncol · 2017 · Derived
    PubMed: PMID 28919011 · NCT01336634 · Neoplasms
  3. Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.
    Planchard D, Kim TM, Mazieres J, et al. · Lancet Oncol · 2017 · Derived
    PubMed: PMID 27080216 · NCT01336634 · Neoplasms
  4. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
    Planchard D, Besse B, Groen HJM, et al. · Lancet Oncol · 2017 · Derived
    PubMed: PMID 27283860 · NCT01336634 · Neoplasms
  5. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
    Long GV, Hauschild A, Santinami M, et al. · N Engl J Med · 2017 · Derived
    PubMed: PMID 28891408 · NCT01682083 (COMBI-AD) · Melanoma
  6. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials.
    Long GV, Grob JJ, Nathan P, et al. · Lancet Oncol · 2017 · Derived
    PubMed: PMID 27864013 · NCT01584648 · Melanoma
  7. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.
    Davies MA, Saiag P, Robert C, et al. · Lancet Oncol · 2017 · Derived
    PubMed: PMID 28592387 · NCT02039947 · Melanoma
  8. Cancer Statistics, 2017.
    Siegel RL, Miller KD, Jemal A, et al. · CA Cancer J Clin · 2017 · Background
    PubMed: PMID 28055103 · NCT03972046 · Melanoma
  9. Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers.
    Grigg C, Blake Z, Gartrell R, et al. · Semin Oncol · 2017 · Background
    PubMed: PMID 28061981 · NCT03972046 · Melanoma
  10. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.
    Dummer R, Schadendorf D, Ascierto PA, et al. · Lancet Oncol · 2017 · Background
    PubMed: PMID 28284557 · NCT04059224 (TraMel-WT) · Melanoma

2016 (7 papers)

  1. Is the NCI MATCH trial a match for gynecologic oncology?
    Moore KN, Mannel RS · Gynecol Oncol · 2016 · Derived
    PubMed: PMID 26586415 · NCT02465060 · Melanoma
  2. Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial.
    Menzies AM, Ashworth MT, Swann S, et al. · Ann Oncol · 2016 · Derived
    PubMed: PMID 25411413 · NCT01584648 · Melanoma
  3. Successful Treatment of a Progressive BRAF V600E-Mutated Anaplastic Pleomorphic Xanthoastrocytoma With Vemurafenib Monotherapy.
    Lee EQ, Ruland S, LeBoeuf NR, et al. · J Clin Oncol · 2016 · Derived
    PubMed: PMID 25092772 · NCT02034110 · Neoplasms
  4. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ, Amonkar MM, Karaszewska B, et al. · Lancet Oncol · 2016 · Derived
    PubMed: PMID 26433819 · NCT01597908 (COMBI-v) · Melanoma
  5. Years of life lost due to metastatic melanoma in 12 countries.
    Thiam A, Zhao Z, Quinn C, et al. · J Med Econ · 2016 · Background
    PubMed: PMID 26531249 · NCT03972046 · Melanoma
  6. Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.
    Coit DG, Thompson JA, Algazi A, et al. · J Natl Compr Canc Netw · 2016 · Background
    PubMed: PMID 27059193 · NCT03972046 · Melanoma
  7. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
    Andtbacka RH, Kaufman HL, Collichio F, et al. · J Clin Oncol · 2016 · Background
    PubMed: PMID 26014293 · NCT03972046 · Melanoma

2015 (6 papers)

  1. Preliminary results from a prospective trial of preoperative combined BRAF and MEK-targeted therapy in advanced BRAF mutation-positive melanoma.
    Johnson AS, Crandall H, Dahlman K, et al. · J Am Coll Surg · 2015 · Trial result
    PubMed: PMID 25797743 · NCT01701037 · Melanoma
  2. Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study.
    Donadieu J, Bernard F, van Noesel M, et al. · Blood · 2015 · Trial result
    PubMed: PMID 26194764 · NCT07022834 · Histiocytosis, Langerhans-Cell
  3. Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma.
    Schadendorf D, Amonkar MM, Stroyakovskiy D, et al. · Eur J Cancer · 2015 · Derived
    PubMed: PMID 25794603 · NCT01584648 · Melanoma
  4. Improved overall survival in melanoma with combined dabrafenib and trametinib.
    Robert C, Karaszewska B, Schachter J, et al. · N Engl J Med · 2015 · Derived
    PubMed: PMID 25399551 · NCT01597908 (COMBI-v) · Melanoma
  5. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.
    Long GV, Stroyakovskiy D, Gogas H, et al. · Lancet · 2015 · Derived
    PubMed: PMID 26037941 · NCT01584648 · Melanoma
  6. BRAF/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib.
    Ranzani M, Alifrangis C, Perna D, et al. · Pigment Cell Melanoma Res · 2015 · Background
    PubMed: PMID 25243813 · NCT04059224 (TraMel-WT) · Melanoma

2014 (3 papers)

  1. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
    Long GV, Stroyakovskiy D, Gogas H, et al. · N Engl J Med · 2014 · Derived
    PubMed: PMID 25265492 · NCT01584648 · Melanoma
  2. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors.
    Ackerman A, Klein O, McDermott DF, et al. · Cancer · 2014 · Derived
    PubMed: PMID 24577748 · NCT01767454 · Melanoma
  3. Erdheim-Chester disease.
    Haroche J, Arnaud L, Cohen-Aubart F, et al. · Curr Rheumatol Rep · 2014 · Background
    PubMed: PMID 24532298 · NCT02281760 · Histiocytosis

2013 (3 papers)

  1. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis.
    Gadner H, Minkov M, Grois N, et al. · Blood · 2013 · Trial result
    PubMed: PMID 23589673 · NCT07022834 · Histiocytosis, Langerhans-Cell
  2. Clofarabine salvage therapy for refractory high-risk langerhans cell histiocytosis.
    Abraham A, Alsultan A, Jeng M, et al. · Pediatr Blood Cancer · 2013 · Trial result
    PubMed: PMID 23255383 · NCT07022834 · Histiocytosis, Langerhans-Cell
  3. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation.
    Haroche J, Cohen-Aubart F, Emile JF, et al. · Blood · 2013 · Background
    PubMed: PMID 23258922 · NCT02281760 · Histiocytosis

2012 (3 papers)

  1. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer.
    Lehmann S, Bykov VJ, Ali D, et al. · J Clin Oncol · 2012 · Background
    PubMed: PMID 22965953 · NCT03391050 · Melanoma
  2. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.
    Hauschild A, Grob JJ, Demidov LV, et al. · Lancet · 2012 · Background
    PubMed: PMID 22735384 · NCT03972046 · Melanoma
  3. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
    Flaherty KT, Infante JR, Daud A, et al. · N Engl J Med · 2012 · Background
    PubMed: PMID 23020132 · NCT03972046 · Melanoma

2011 (1 paper)

  1. Resistance to BRAF inhibition in melanomas.
    Solit DB, Rosen N · N Engl J Med · 2011 · Background
    PubMed: PMID 21345109 · NCT03972046 · Melanoma

2009 (1 paper)

  1. 2'-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH-S-98 protocol of the Histiocyte Society.
    Weitzman S, Braier J, Donadieu J, et al. · Pediatr Blood Cancer · 2009 · Trial result
    PubMed: PMID 19731321 · NCT07022834 · Histiocytosis, Langerhans-Cell

2008 (1 paper)

  1. Clofarabine in refractory Langerhans cell histiocytosis.
    Rodriguez-Galindo C, Jeng M, Khuu P, et al. · Pediatr Blood Cancer · 2008 · Trial result
    PubMed: PMID 18623218 · NCT07022834 · Histiocytosis, Langerhans-Cell

2004 (1 paper)

  1. Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group.
    Haupt R, Nanduri V, Calevo MG, et al. · Pediatr Blood Cancer · 2004 · Trial result
    PubMed: PMID 15049016 · NCT07022834 · Histiocytosis, Langerhans-Cell

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).